 Shares of TG Therapeutics Inc. TGTX, -21.85 tumbled 24.2 in trading on Monday following the companys announcement on Friday that it had withdrawn an application to get Food and Drug Administration approval for ublituximab and Ukoniq as a treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma. TG said in a news release that it decided to withdraw the application due to updated survival data from a Phase 3 clinical trial. 